Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Cash from Operations: 2022-2025

Historic Cash from Operations for Gossamer Bio (GOSS) over the last 4 years, with Sep 2025 value amounting to -$36.2 million.

  • Gossamer Bio's Cash from Operations fell 12.91% to -$36.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.4 million, marking a year-over-year decrease of 11128.42%. This contributed to the annual value of -$3.5 million for FY2024, which is 97.82% up from last year.
  • Latest data reveals that Gossamer Bio reported Cash from Operations of -$36.2 million as of Q3 2025, which was up 23.15% from -$47.1 million recorded in Q2 2025.
  • In the past 5 years, Gossamer Bio's Cash from Operations ranged from a high of $116.3 million in Q2 2024 and a low of -$53.5 million during Q1 2022.
  • For the 3-year period, Gossamer Bio's Cash from Operations averaged around -$26.0 million, with its median value being -$36.2 million (2025).
  • Its Cash from Operations has fluctuated over the past 5 years, first spiked by 404.17% in 2024, then tumbled by 140.45% in 2025.
  • Gossamer Bio's Cash from Operations (Quarterly) stood at -$47.7 million in 2022, then grew by 29.97% to -$33.4 million in 2023, then decreased by 6.15% to -$35.5 million in 2024, then declined by 12.91% to -$36.2 million in 2025.
  • Its Cash from Operations was -$36.2 million in Q3 2025, compared to -$47.1 million in Q2 2025 and -$39.7 million in Q1 2025.